Suppress the proliferation process of glioblastoma by breaking off the tumor - microenvironment interaction by CRIPSR -mediated technology
DOI:
https://doi.org/10.61173/kmv30630Keywords:
CRIPSR -mediated technology, glioblasto-ma, cancer, gene therapyAbstract
Glioblastoma is a notorious malignant tumor and traits in cancer provide strong drug resistance. Current Traditional clinical treatments include chemotherapy and surgery, had been proved that showed insufficient effect towards glioblastoma, leading to the requirement of new therapy ------ CRISPR mediated technology therapy application. CRISPR is prior options for gene therapy drug design and using gene-editing principle from the molecular level. Scientists research evaluated the CRIPSR gene therapy had ability in editing related functions of glioblastomas and inducing an immune response by blocking the metabolic activity of cancer cells to achieve anti-cancer effects. We discussed the recent identified potential CRISPR gene therapy targeting sites in glioblastoma gene therapy, including clinical traits and in vivo experiments verified the value in future clinical treatment applications. We also discussed the relationship between the target sites of the glioblastoma genome and the traits they related with. Targeting the angiogenesis regulator factors leads to suppression of glioblastoma proliferation and inhibit the tumor growth. Mediated the tumor micro environment by enhancing antigen present process and reduce glioblastoma interaction with immune cells, could up regulated the anti-tumor immune response. The is also a possibility of combining immune therapy and CRIPSR gene editing therapy together by Car-T therapy. We also discuss the potential delivery method for CRISPR gene-editing therapy, compare the AAV virus method and nanocapsule for assist the edited gene reach the target sties and avoid off-target rate. The CRISPR therapy could be the mainstay in glioblastoma treatment by directly target the glioblastoma metabolism to inhibit tumor proliferation, and could increase survival rate in child glioblastoma treatment as the heterogeneity of glioblastoma is high.
References
[1] Watson SS, Zomer A, Fournier N, Lourenco J, Quadroni M, Chryplewicz A, et al. Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence. Cancer Cell. 2024 Sep 9;42(9):1507-1527.e11.
[2] Lee S, Weiss T, Bühler M, Mena J, Lottenbach Z, Wegmann R, et al. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nat Med. 2024 Nov;30(11):3196–208.
[3] Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020 Jul 15;10(1):11622.
[4] Zhang H, Zhou Y, Cui B, Liu Z, Shen H. Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma. Biomed Pharmacother. 2020 Jun 1;126:110086.
[5] Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006 Jul;13(7):1238–41.
[6] Zanders ED, Svensson F, Bailey DS. Therapy for glioblastoma: is it working? Drug Discov Today. 2019 May;24(5):1193–201.
[7] Li J, Wang W, Wang J, Cao Y, Wang S, Zhao J. Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma. Front Oncol. 2021;11:678226.
[8] Begagić E, Bečulić H, Đuzić N, Džidić-Krivić A, Pugonja R, Muharemović A, et al. CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review. Biomedicines. 2024 Jan 21;12(1):238.
[9] Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020 Nov 16;11(1):5820.
[10] Rayati M, Mansouri V, Ahmadbeigi N. Gene therapy in glioblastoma multiforme: Can it be a role changer? Heliyon. 2024 Mar 15;10(5):e27087.
[11] Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer. 2018 Nov;119(10):1171–81.
[12] Chada S, Wiederhold D, Menander KB, Sellman B, Talbott M, Nemunaitis JJ, et al. Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer Gene Ther. 2022 Jun;29(6):825–34.
[13] Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022 May;22(5):259–79.
[14] Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/ Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023 Jan 16;8(1):1–23.
[15] De Castro V, Galaine J, Loyon R, Godet Y. CRISPR- Cas gene knockouts to optimize engineered T cells for cancer immunotherapy. Cancer Gene Ther. 2024 Aug;31(8):1124–34.
[16] Zhao Y, Qin J, Yu D, Liu Y, Song D, Tian K, et al. Polymerlocking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2024 Dec;19(12):1869–79.
[17] Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR- Cas immune system: biology, mechanisms and applications. Dean&Francis ISSN 2959-409X Biochimie. 2015 Oct;117:119–28.
[18] Hossain MA. CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing. Prog Mol Biol Transl Sci. 2021;178:63–83.
[19] Adler BA, Hessler T, Cress BF, Lahiri A, Mutalik VK, Barrangou R, et al. Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing. Nat Microbiol. 2022 Dec;7(12):1967–79.
[20] Teufel M, Klein CA, Mager M, Sobetzko P. A multifunctional system for genome editing and large-scale interspecies gene transfer. Nat Commun. 2022 Jun 14;13(1):3430.
[21] Marraffini LA, Sontheimer EJ. CRISPR interference: RNA- directed adaptive immunity in bacteria and archaea. Nat Rev Genet. 2010 Mar;11(3):181–90.
[22] Bi M, Su W, Li J, Mo X. Insights into the inhibition of protospacer integration via direct interaction between Cas2 and AcrVA5. Nat Commun. 2024 Apr 16;15(1):3256.
[23] Karginov FV, Hannon GJ. The CRISPR system: small RNA- guided defense in bacteria and archaea. Mol Cell. 2010 Jan 15;37(1):7.
[24] McCarty NS, Graham AE, Studená L, Ledesma-Amaro R. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nat Commun. 2020 Mar 9;11(1):1281.
[25] Morisaka H, Yoshimi K, Okuzaki Y, Gee P, Kunihiro Y, Sonpho E, et al. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun. 2019 Dec 6;10(1):5302.
[26] Krysler AR, Cromwell CR, Tu T, Jovel J, Hubbard BP. Guide RNAs containing universal bases enable Cas9/Cas12a recognition of polymorphic sequences. Nat Commun. 2022 Mar 25;13(1):1617.
[27] Bravo JPK, Liu MS, Hibshman GN, Dangerfield TL, Jung K, McCool RS, et al. Structural basis for mismatch surveillance by CRISPR-Cas9. Nature. 2022 Mar;603(7900):343–7.
[28] Wang C, Qu Y, Cheng JKW, Hughes NW, Zhang Q, Wang M, et al. dCas9-based gene editing for cleavage-free genomic knock-in of long sequences. Nat Cell Biol. 2022 Feb;24(2):268– 78.
[29] Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014 Nov 28;346(6213):1258096.
[30] Zhao L, Koseki SRT, Silverstein RA, Amrani N, Peng C, Kramme C, et al. PAM-flexible genome editing with an engineered chimeric Cas9. Nat Commun. 2023 Oct 4;14(1):6175.
[31] Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022 May;22(5):259–79.
[32] Pacesa M, Loeff L, Querques I, Muckenfuss LM, Sawicka M, Jinek M. R-loop formation and conformational activation mechanisms of Cas9. Nature. 2022 Sep;609(7925):191–6.
[33] Nemudraia A, Nemudryi A, Wiedenheft B. Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in human cells. Science. 2024 May 17;384(6697):808–14.
[34] Using Genes to Cure Cancer. Cell. 1999 Sep 17;98(6):728– 30.
[35] Ishibashi A, Saga K, Hisatomi Y, Li Y, Kaneda Y, Nimura K. A simple method using CRISPR-Cas9 to knock-out genes in murine cancerous cell lines. Sci Rep. 2020 Dec 18;10(1):22345.
[36] Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024 May;30(5):1320–9.
[37] Zhou S, Lin W, Jin X, Niu R, Yuan Z, Chai T, et al. CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells. Cell Rep Med. 2024 Dec 17;5(12):101844.
[38] Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024 Apr 11;390(14):1290–8.
[39] Jiang L, You F, Wu H, Qi C, Xiang S, Zhang P, et al. B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad- Spectrum Activity against Solid Tumors. Cancer Res. 2024 Dec 2;84(23):4066–80.
[40] Chen Y, Chen M, Kuo T, Zhou K, Jin S, Liu M, et al. NXL- 004: A novel trans-differentiation therapy for glioblastoma treatment. NaN. 2024;(16_suppl):e14020–e14020.
[41] Li X, Zhao L, Li W, Gao P, Zhang N. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Genes Immun. 2024 Jun;25(3):201–8.
[42] Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF, et al. Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker. Nat Commun. 2024 Nov 9;15(1):9718.
[43] Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, Sun MY, et al. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neuro-Oncol. 2019 Nov 4;21(11):1436–46.
[44] Guégan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med. 2024 Dec;5(12):101831.
[45] Liu R, Ren X, Park YE, Feng H, Sheng X, Song X, et al. Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis. Cell Metab [Internet]. 2024 Dec 5 [cited 2024 Dec 27];0(0). Available from: https://www.cell.com/cell-metabolism/abstract/S1550- 4131(24)00451-0
[46] Xiong Q, Zhu J, Zhang Y, Deng H. CAR-NK cell therapy for glioblastoma: what to do next? Front Oncol [Internet]. 2023 Jun 19 [cited 2024 Dec 27];13. Available from: https:// www.frontiersin.org/journals/oncology/articles/10.3389/ Dean&Francis Wei Wang fonc.2023.1192128/full
[47] Zhao L, Qiu Z, Yang Z, Xu L, Pearce TM, Wu Q, et al. Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism. Nat Cancer. 2024 Jan;5(1):147–66.
[48] Tatla AS, Justin AW, Watts C, Markaki AE. A vascularized tumoroid model for human glioblastoma angiogenesis. Sci Rep. 2021 Oct 1;11(1):19550.
[49] Guarnaccia L, Navone SE, Trombetta E, Cordiglieri C, Cherubini A, Crisà FM, et al. Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy. Sci Rep. 2018 Jun 8;8(1):8748.
[50] Pichol-Thievend C, Anezo O, Pettiwala AM, Bourmeau G, Montagne R, Lyne AM, et al. VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance. Nat Commun. 2024 Apr 29;15(1):3602.
[51] Spinelli C, Adnani L, Meehan B, Montermini L, Huang S, Kim M, et al. Mesenchymal glioma stem cells trigger vasectasia—distinct neovascularization process stimulated by extracellular vesicles carrying EGFR. Nat Commun. 2024 Apr 3;15(1):2865.
[52] Liang J, Jin Z, Kuang J, Feng H, Zhao Q, Yang Z, et al. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer. 2021 Aug;125(3):390–401.
[53] Choi SH, Jang J, Kim Y, Park CG, Lee SY, Kim H, et al. ID1high/activin Ahigh glioblastoma cells contribute to resistance to anti-angiogenesis therapy through malformed vasculature. Cell Death Dis. 2024 Apr 24;15(4):1–10.
[54] Pfeifer M, Brammeld JS, Price S, Pilling J, Bhavsar D, Farcas A, et al. Genome-wide CRISPR screens identify the YAP/ TEAD axis as a driver of persister cells in EGFR mutant lung cancer. Commun Biol. 2024 Apr 24;7(1):1–16.
[55] Chen Y, Zhang Y. Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. Adv Sci Weinh Baden- Wurtt Ger. 2018 Jun;5(6):1700964.
[56] Wang F, Zhang S, Sun F, Chen W, Liu C, Dong H, et al. Antiangiogenesis and anti-immunosuppression gene therapy through targeting COUP-TFII in an in situ glioblastoma mouse model. Cancer Gene Ther. 2024 Aug;31(8):1135–50.
[57] Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023 May 11;8(1):1–39.
[58] Polvani S, Pepe S, Milani S, Galli A. COUP-TFII in Health and Disease. Cells. 2019 Dec 31;9(1):101.
[59] Bao Y, Gu D, Feng W, Sun X, Wang X, Zhang X, et al. COUP-TFII regulates metastasis of colorectal adenocarcinoma cells by modulating Snail1. Br J Cancer. 2014 Aug;111(5):933– 43.
[60] Xu M, Qin J, Tsai SY, Tsai M jer. The role of the orphan nuclear receptor COUP-TFII in tumorigenesis. Acta Pharmacol Sin. 2015 Jan;36(1):32–6.
[61] Ravi VM, Neidert N, Will P, Joseph K, Maier JP, Kückelhaus J, et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun. 2022 Feb 17;13(1):925.
[62] Liu I, Hack OA, Filbin MG. The imitation game: How glioblastoma outmaneuvers immune attack. Cell. 2021 Apr 29;184(9):2278–81.
[63] Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, et al. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Front Immunol. 2020;11:582106.
[64] Bae E, Huang P, Müller-Greven G, Hambardzumyan D, Sloan AE, Nowacki AS, et al. Integrin α3β1 promotes vessel formation of glioblastoma-associated endothelial cells through calcium-mediated macropinocytosis and lysosomal exocytosis. Nat Commun. 2022 Jul 25;13(1):4268.
[65] Zhou S, Huang Y, Chen Y, Liu Y, Xie L, You Y, et al. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nat Commun. 2023 Jan 26;14(1):435.
[66] Mayer S, Milo T, Isaacson A, Halperin C, Miyara S, Stein Y, et al. The tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts. Nat Commun. 2023 Sep 19;14(1):5810.
[67] Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neuro-Oncol Adv. 2023;5(1):vdad009.
[68] Yang K, Rich JN. A delicate initiation: Lipolysis of lipid droplets fuels glioblastoma. Mol Cell. 2021 Jul 1;81(13):2686–7.
[69] Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016 Jan;5(1):e189–e189.
[70] Governa V, de Oliveira KG, Bång-Rudenstam A, Offer S, Cerezo-Magaña M, Li J, et al. Protumoral lipid dropletloaded macrophages are enriched in human glioblastoma and can be therapeutically targeted. Sci Transl Med. 2024 Oct 30;16(771):eadk1168.
[71] Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024 Apr;30(4):1001–12.
[72] Chaligne R, Gaiti F, Silverbush D, Schiffman JS, Weisman HR, Kluegel L, et al. Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states. Nat Genet. 2021 Oct;53(10):1469–79.
[73] Dong Z, Cui H. Epigenetic modulation of metabolism in glioblastoma. Semin Cancer Biol. 2019 Aug;57:45–51.
[74] Lavogina D, Krõlov MK, Vellama H, Modhukur V, Di Nisio V, Lust H, et al. Inhibition of epigenetic and cell cyclerelated targets in glioblastoma cell lines reveals that onametostat reduces proliferation and viability in both normoxic and hypoxic Dean&Francis ISSN 2959-409X conditions. Sci Rep. 2024 Feb 21;14(1):4303.
[75] Lavogina D, Laasfeld T, Vardja M, Lust H, Jaal J. Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets. Sci Rep. 2021 Oct 13;11:20338.
[76] Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell. 2024 Jan 18;187(2):446-463.e16.
[77] Eisenbarth D, Wang YA. Glioblastoma heterogeneity at single cell resolution. Oncogene. 2023 Jun;42(27):2155–65.
[78] Xie T, Danieli-Mackay A, Buccarelli M, Barbieri M, Papadionysiou I, D’Alessandris QG, et al. Pervasive structural heterogeneity rewires glioblastoma chromosomes to sustain patient-specific transcriptional programs. Nat Commun. 2024 May 9;15(1):3905.
[79] Wenger A, Carén H. Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. Cancers. 2022 Jan;14(22):5679.
[80] Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med. 2018 Oct;24(10):1611–24.
[81] Chapman OS, Luebeck J, Sridhar S, Wong ITL, Dixit D, Wang S, et al. Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. Nat Genet. 2023 Dec;55(12):2189–99.
[82] Kim H, Kim S, Wade T, Yeo E, Lipsa A, Golebiewska A, et al. Mapping extrachromosomal DNA amplifications during cancer progression. Nat Genet. 2024 Nov;56(11):2447–54.
[83] Bailey C, Pich O, Thol K, Watkins TBK, Luebeck J, Rowan A, et al. Origins and impact of extrachromosomal DNA. Nature. 2024 Nov;635(8037):193–200.
[84] Noorani I, Mischel PS, Swanton C. Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. Nat Rev Clin Oncol. 2022 Nov;19(11):733–43.
[85] Luebeck J, Ng AWT, Galipeau PC, Li X, Sanchez CA, Katz-Summercorn AC, et al. Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus. Nature. 2023 Apr;616(7958):798–805.
[86] Tang J, Weiser NE, Wang G, Chowdhry S, Curtis EJ, Zhao Y, et al. Enhancing transcription–replication conflict targets ecDNA-positive cancers. Nature. 2024 Nov;635(8037):210–8.
[87] Jang HJ, Shah NM, Maeng JH, Liang Y, Basri NL, Ge J, et al. Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells. Nat Genet. 2024 Sep;56(9):1903–13.
[88] Rao R, Han R, Ogurek S, Xue C, Wu LM, Zhang L, et al. Glioblastoma genetic drivers dictate the function of tumorassociated macrophages/microglia and responses to CSF1R inhibition. Neuro-Oncol. 2022 Apr 1;24(4):584–97.
[89] Xing Z, Wang C, Yang W, She D, Yang X, Cao D. Predicting glioblastoma recurrence using multiparametric MR imaging of non-enhancing peritumoral regions at baseline. Heliyon. 2024 Apr 26;10(9):e30411.
[90] Watson SS, Zomer A, Fournier N, Lourenco J, Quadroni M, Chryplewicz A, et al. Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence. Cancer Cell. 2024 Sep 9;42(9):1507-1527.e11.
[91] Kang X, Wang Y, Liu P, Huang B, Zhou B, Lu S, et al. Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene- Editing in Glioma Studies. Cancers. 2023 Jan;15(2):396.
[92] Bader JE, Wolf MM, Lupica-Tondo GL, Madden MZ, Reinfeld BI, Arner EN, et al. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature. 2024 Jun;630(8018):968–75.
[93] Davies D, Kamdar S, Woolf R, Zlatareva I, Iannitto ML, Morton C, et al. PD-1 defines a distinct, functional, tissueadapted state in Vδ1+ T cells with implications for cancer immunotherapy. Nat Cancer. 2024 Mar;5(3):420–32.
[94] Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, et al. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020 Jul 6;11(7):1–16.
[95] Litak J, Mazurek M, Grochowski C, Kamieniak P, Roliński J. PD-L1/PD-1 Axis in Glioblastoma Multiforme. Int J Mol Sci. 2019 Oct 28;20(21):5347.
[96] Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.
[97] Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024 May 18;23(1):108.
[98] Schillebeeckx I, Earls J, Flanagan KC, Hiken J, Bode A, Armstrong JR, et al. T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. Sci Rep. 2022 Jan 25;12(1):1342.
[99] von Roemeling CA, Patel JA, Carpenter SL, Yegorov O, Yang C, Bhatia A, et al. Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade. Nat Commun. 2024 Jul 12;15(1):5871.
[100] Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol [Internet]. 2017 Aug 23 [cited 2024 Dec 27];8. Available from: https://www.frontiersin.org/journals/ pharmacology/articles/10.3389/fphar.2017.00561/full
[101] Fierro J, DiPasquale J, Perez J, Chin B, Chokpapone Y, Tran AM, et al. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization. Sci Rep. 2022 Feb 14;12(1):2417.
[102] Macciò A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1-polarized tumor-associated Dean&Francis Wei Wang macrophages in the prognosis of advanced ovarian cancer patients. Sci Rep. 2020 Apr 8;10(1):6096.
[103] Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022 Nov;21(11):799–820.
[104] Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, et al. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2021 Dec;2(12):1372–86.
[105] Wang X, Fukumoto T, Noma K ichi. Therapeutic strategies targeting cellular senescence for cancer and other diseases. J Biochem (Tokyo). 2024 Feb 15;175(5):525–37.
[106] Fyfe I. CAR T cells offer hope in glioblastoma. Nat Rev Neurol. 2024 Jun;20(6):315.
[107] El Baba R, Pasquereau S, Haidar Ahmad S, Monnien F, Abad M, Bibeau F, et al. EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes. Oncogene. 2023 Jun;42(24):2031–45.
[108] Li F, Yang K, Gao X, Zhang M, Gu D, Wu X, et al. A peptide encoded by upstream open reading frame of MYC binds to tropomyosin receptor kinase B and promotes glioblastoma growth in mice. Sci Transl Med. 2024 Oct 2;16(767):eadk9524.
[109] Pihlajamaa P, Kauko O, Sahu B, Kivioja T, Taipale J. A competitive precision CRISPR method to identify the fitness effects of transcription factor binding sites. Nat Biotechnol. 2023 Feb;41(2):197–203.
[110] Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol. 2024 Nov 12;
[111] Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024 May;30(5):1320–9.
[112] Li X, Zhao L, Li W, Gao P, Zhang N. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Genes Immun. 2024 Jun;25(3):201–8.
[113] Pant A, Lim M. CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement. Cancers. 2023 Feb 16;15(4):1249.
[114] Nishimura CD, Corrigan D, Zheng XY, Galbo PM, Wang S, Liu Y, et al. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors. Sci Adv. 2024 May 10;10(19):eadk1857.
[115] Prattapong P, Ngernsombat C, Aimjongjun S, Janvilisri T. CRISPR/Cas9‐mediated double knockout of SRPK1 and SRPK2 in a nasopharyngeal carcinoma cell line. Cancer Rep. 2019 Nov 27;3(2):e1224.
[116] Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, et al. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer. 2021 Dec;2(12):1406–22.
[117] Park JH, Hothi P, de Lomana ALG, Pan M, Calder R, Turkarslan S, et al. Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells. Sci Adv. 2024 Jun 7;10(23):eadj7706.
[118] Dewdney B, Jenkins MR, Best SA, Freytag S, Prasad K, Holst J, et al. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress. Signal Transduct Target Ther. 2023 Oct 20;8(1):400.
[119] Castellan M, Guarnieri A, Fujimura A, Zanconato F, Battilana G, Panciera T, et al. Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma. Nat Cancer. 2021 Feb;2(2):174–88.
[120] Das KK, Kumar R. Pediatric Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 [cited 2024 Dec 27]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK469983/
[121] Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler- Reya R, Hoang-Minh LB, et al. The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022 Jan;3(1):11–24.
[122] Dubois FPB, Shapira O, Greenwald NF, Zack T, Wala J, Tsai JW, et al. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022 Aug;3(8):994–1011.
[123] Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018 May 15;9(1):1911.
[124] Ahmadi SE, Soleymani M, Shahriyary F, Amirzargar MR, Ofoghi M, Fattahi MD, et al. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Casmediated cancer therapy. Cancer Gene Ther. 2023 Jul;30(7):936– 54.
[125] Fuentes CM, Schaffer DV. Adeno-associated virus-mediated delivery of CRISPR-Cas9 for genome editing in the central nervous system. Curr Opin Biomed Eng. 2018 Sep;7:33–41.
[126] Li A, Lee CM, Hurley AE, Jarrett KE, De Giorgi M, Lu W, et al. A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing. Mol Ther Methods Clin Dev. 2019 Mar 15;12:111–22.
[127] Wang Y, Jiang H, Li M, Xu Z, Xu H, Chen Y, et al. Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy. Gene. 2024 Nov 15;927:148733.
[128] Torregrosa T, Lehman S, Hana S, Marsh G, Xu S, Koszka K, et al. Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice. Gene Ther. 2021 Aug;28(7):456–68.
[129] Song R, Pekrun K, Khan TA, Zhang F, Paşca SP, Kay MA. Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model. Mol Ther Methods Clin Dev. 2022 Dec 8;27:73–88.
[130] Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno- Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs Clin Immunother Biopharm Gene Ther. 2017 Aug;31(4):317–34.
[131] Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the Dean&Francis ISSN 2959-409X CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release Off J Control Release Soc. 2017 Nov 28;266:17–26.
[132] Zou Y, Sun X, Yang Q, Zheng M, Shimoni O, Ruan W, et al. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv. 2022 Apr 22;8(16):eabm8011.
[133] Solanki C, Sadana D, Arimappamagan A, Rao KVLN, Rajeswaran J, Subbakrishna DK, et al. Impairments in Quality of Life and Cognitive Functions in Long-term Survivors of Glioblastoma. J Neurosci Rural Pract. 2017;8(2):228–35.
[134] Zhang D, Zhang Z, Unver T, Zhang B. CRISPR/Cas: A powerful tool for gene function study and crop improvement. J Adv Res. 2021 Mar;29:207–21.
[135] De Castro V, Galaine J, Loyon R, Godet Y. CRISPR- Cas gene knockouts to optimize engineered T cells for cancer immunotherapy. Cancer Gene Ther. 2024 Aug;31(8):1124–34.
[136] Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022 May;22(5):259–79.
[137] Yuen CA, Pekmezci M, Bao S, Kong XT. Metastatic glioblastoma to the lungs: a case report and literature review. CNS Oncol. 2024 Jun 6;13(1):2351789.
[138] Wu W, Zhong D, Zhao Z, Wang W, Li J, Zhang W. Postoperative extracranial metastasis from glioblastoma: a case report and review of the literature. World J Surg Oncol. 2017 Dec 29;15(1):231.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
